Category: Health

Medisun launched the “Hong Kong Regenerative Medisun Association”

On May 28, 2018, the Hong Kong Regenerative Medisun Association, which was initiated by representatives from the Hong Kong Regenerative Medisun Industry and academic circles, was formally established under the auspices of the Medisun Medical Group.

Hong Kong Regenerative Medisun Association goals

The Hong Kong Regenerative Medisun Association was founded by experts, scholars, industry representatives and people of insight in the field of regenerative Medisun in Hong Kong and around the world. The purpose of the association is to establish a consensus platform for the regenerative Medisun industry in Hong Kong, promote the development of the regenerative Medisun industry, encourage and promote international cooperation, and propose to the Hong Kong SAR government the recommendations of the regenerative Medisun industry on industry regulations and actively influence industry rules. The establishment and improvement of the company provides effective technical and management advice to the Hong Kong government, Hong Kong public health agencies and companies in the industry.

The first meeting of the Hong Kong Regenerative Medisun Association (May 28, 2018)

On the afternoon of May 28, representatives from Hong Kong’s medical health, regenerative Medisun and biotechnology fields, doctors, pharmacists, chemists and university researchers gathered to discuss and elect the first council of the Hong Kong Regenerative Medisun Association.They read the charter of the association and clarify the duties of the board. At the same time, they have had a heated discussion on the regulatory documents issued by the Hong Kong SAR Government on Advanced Therapy Products. They agreed to regulate the direction of document guidance and proposed a number of issues that need to be clarified, including:

1. Professional qualifications required by the licensee of the Regenerative Medisun and Stem Cell Research and Development Organization;

2. Advanced Therapy Products is regulated by the Pharmacy and Poisons Ordinance (Cap. 138). However, since the production process and user definition of cellular products and pharmaceutical products are different, they should be clarified accordingly;

3. With reference to the requirements of the international GMP/PICS standard, which standard should be achieved in the cell laboratory qualification of existing regenerative Medisun institutions;

4. After the specific regulation is in force, whether there should be a transition period, so that the industry has time to adjust and cooperate;

5. Submit the Advanced Therapy Products comments and submit them to the Hong Kong Department of Health.

Member of the First Council of the Hong Kong Regenerative Medisun Association

Position	Name	Qualifications
Chairman	Danny Wong Mr. Wang Xiaofeng	Founder and Chairman of Medisun Medical Group, years of investment experience in the field of regenerative Medisun, understanding the development and trends of the biotechnology industry
Vice President	Joseph Wang  Dr. Wang Qiyuan	Registered as a doctor, founder of the Hong Kong Stem Cell Center, enriching the clinical experience of regenerative Medisun
Vice President	David Leung Mr. Liang Yaoming	Registered pharmacist, familiar with pharmaceutical regulations and GMP requirements
Vice Chairman	Gregory Cheng Professor Zheng Yanming	Hematology expert, Professor of the University of Macau Health Sciences
Director | Treasurer	Kenneth Lee Dr. Li Zhisheng	Registered as a doctor, B Q Anti-aging Center Consultant
Director	Philip Choy Dr. Cai Shaolong	Ph.D. in Natural Medisun, Madison Biomedical Director
Director	Daniel Tam Dr. Tan Yizhu	Registered as a medical laboratory technologist, director of the Trans-Olympic Blood Bank Laboratory, focusing on cell culture technology for many years
Director	Vivien Leung Ms. Liang Yiqun	Registered as a medical laboratory technologist, manager of the Trans-Olympic Blood Bank Laboratory, familiar with quality management
Director	Chris Wong Dr. Huang Libao	Registered as a medical laboratory technologist, director of HKMDPC, molecular biodiagnostic expert
Secretary	Sidney Tam Dr. Tan Guozhen	Chief Executive Officer, Life Clinic, Health Management Consultant
Secretary	Allen Chan Mr. Chen Yuxin	Registered as a medical laboratory technologist, familiar with quality management

The first meeting of the Hong Kong Regenerative Medisun Association (May 28, 2018)

Hong Kong Regenerative Medisun Association’s recent work plan

Next, the Hong Kong Regenerative Medisun Association will issue letters to the organizations including the Hong Kong Department of Health, the Hong Kong Stock Exchange, the Hong Kong University Biomedical Science, Life Sciences, and the Global Regenerative Medisun Alliance (ARM). include:

1. Announced the official establishment of the Hong Kong Regenerative Medisun Association

2. Announce the initial membership list of the Hong Kong Regenerative Medisun Council, association charter, association vision and goals

3. Call for the support and participation of experts, scholars and industry representatives from Hong Kong and around the world

4. Propose to the Hong Kong Government to clarify regulatory regulations on Advanced Medisun and Advanced Therapy Products

Special thanks

Thank you for taking the time to attend the representatives of the institutions, including:

Medisun Medical Group | Medisun Reproductive Medisun Center

Hong Kong Life Science and Technology Group Co., Ltd.

Standard Pathology Laboratory Co., Ltd.

BIH

Living Tissues company limited

BIB Health Care Centre

Hongxin Medical Center

Austa beauty

Hong Kong International Regenerative Medisun Centre

HKMPDC

Huixin Technology

Guangzhou Biological Institute

Trans-along cord blood bank

Hong Kong Stem Cell Center

Life Length

Biocell

Cordlife

For more information, please visit http://www.medisun.hk/

The famous American vaccine company Profectus settled in Hong Kong

First recommend HPV cervical cancer treatment vaccine

BALTIMORE, MARYLAND, USA and HONG KONG, April 20, 2018

Profectus Biotech and Medisun Medical Group today announced the opening of a new joint venture in Hong Kong. The primary mission of the new company, ProMed BioSciences, Ltd., is to establish a leading vaccine company focused on the development of preventive and therapeutic vaccines for infectious diseases and cancer. The joint venture will leverage Profectus’ vaccine development expertise, clinically proven vaccine platform technology and a developing vaccine product line, in line with Medisun’s expertise, established clinical network and market access capabilities, expected in the second half of 2018 to put into operation.

The company’s first product development program will focus on the development, production and commercial application of prophylactic and therapeutic vaccines for HPV (human papillomavirus)-related lesions and cervical cancer [based on PBSVax® technology developed by Profectus]. ProMed BioSciences also plans to develop and treat hepatitis C virus (HCV), hepatitis B virus (HBV), herpes simplex virus (HSV), respiratory syncytial virus (RSV), and human immunodeficiency virus (HIV). Chikungunya and Zika, as well as personalized vaccines to treat cancer. The joint venture is expected to launch new vaccines in their respective markets, which will help promote the development of new vaccines, but ultimately the goal is to benefit patients around the world.

Mr. Jeffery Meshulam (first from left), President of Profectus Biotechnology, Mr. Terry Lierman (second from left), Chairman of Medivh Medical Group, and Mr. Danny Wong (fourth from right), founder and executive chairman of Medisun Medical Group, at Profectus ,USA.

– Long-term strategic cooperation to address the huge demand for prevention and treatment of infectious diseases and cancer in Asia

-Profectus’ expertise in vaccine development and platform technology, combined with Medisun’s localized expertise and experience, to establish a leading Hong Kong vaccine company focused on serving Asia

“This strategic cooperation will help establish Profectus’ business in Hong Kong and China. Through close cooperation with Medisun, we can assist Hong Kong and China to develop advanced vaccine technology to help prevent and treat Asian patients. Mr. Jeffrey Meshulam, President of Profectus, said, “We are pleased to be able to work with recognized local partners to achieve the highest standards of scientific research and development integration and medical services.”

“This collaboration will help Profectus and Medisun to jointly produce life-saving vaccines for infectious diseases and cancer, and address the huge medical needs that have not been met in Hong Kong, China and Asia.” Mr. Danny Wong, founder and executive chairman of Medisun Medical Group, said “ProMed BioSciences will leverage Profectus’ expertise in vaccine development and technology, combined with Medisun’s local expertise and close links with healthcare facilities in Hong Kong and China, and government medical regulatory agencies to develop vaccines to provide leadership for Asian patients disease prevention and treatment programs.”

ProMed BioSciences will focus on the following:

• Conduct technical research in Hong Kong or China

• Conduct clinical trials in Hong Kong or China

• Promote the expansion of Medisun Medical Center

• Develop vaccines to address disease prevention needs

• leverage to maximize the expertise of both partners

Mr. Jeffery Meshulam, President of Profectus Biotechnology (first from left), Mr. Terry Lierman, Chairman of Medisun Medical Group (first from right), Mr. Danny Wong, founder and executive chairman of Medisun Medical Group (middle), at the US headquarters of  Profectus.

About ProMed BioSciences

ProMed BioSciences Limited is a joint venture between Profectus BioSciences (USA) and Medisun Medical Group (Hong Kong) in Hong Kong to develop and conduct new vaccine clinical trials and commercial applications to address infectious diseases and cancer in Asia with the huge demand for prevention and treatment.

About Medisun

Headquartered in Hong Kong, Medisun Medical Group is a professional medical investment group dedicated to the research and development and commercialization of global regenerative Medisunne products, as well as quality hospitals and treatment centers. Medisun invests extensively in the fields of regenerative and stem cell patent technology, including stem cell therapy for heart failure, stem cell therapy for liver disease, kidney disease, nervous system disease, cancer, AIDS, and immune cell therapy for a variety of cancers. Medisun and Harvard University Stem Cell Research Institute, Johns Hopkins Medical School Life Science Center, Tsinghua University and other institutions have long-term cooperation plans to jointly invest in regenerative and stem cell therapy technology, with Medisun as a cooperative business The holding entity and holds global intellectual property rights. Medisun and the University of Maryland’s Institute of Human Virology (IHV) set up a technology clinical trial and development platform for viruses and cancer. Based on the Medisun Biomedical Laboratory in Hong Kong, Radiation will jointly build medical clinics in China and Asia. The experimental resource network promotes the world’s largest clinical research and development platform for virus research and cancer treatment technology. The Medisun Reproductive Centre is located at the Proud Square in Kowloon Bay, Hong Kong. It has a 50,000 square foot stem cell GMP production base, a cancer treatment centre and an anti-aging centre. It brings together European, Japanese, American and individual Chinese experts to develop a rigorous and professional R&D process. Provides immune cell therapy and a variety of stem cell health treatments.

For more information, please visit http://www.medisun.hk/

About Profectus BioSciences

Profectus BioSciences is a clinical stage vaccine development company focused on developing new vaccines for infectious disease and cancer prevention and treatment. The Profectus vaccine is based primarily on the company’s proprietary VesiculoVax™ and DNA vaccine technology platform. By simply using the VesiculoVax™ vaccine alone, B cells can be rapidly expanded to provide protection against emerging infectious diseases that threaten public health and biodefense mechanisms, such as Ebola, Marburg, Chikungunya, Zika virus, equine encephalitis virus, and respiratory syncytial virus. When VesiculoVax™ is used as a vaccine when the immune system is launched with the best pDNA vaccine, the Vesiculo Vax™-directed vaccine expands the triggered T cells into effector cells, which are ideal for attacking virus-infected cells and cancer. Current projects using the Prime / Boost Vaccine System (PBS Vax™) strategy include hepatitis B virus (HBV), human papillomavirus (HPV), herpes simplex virus type 2 (HSV-2) and human immunodeficiency virus ( HIV). Partners and collaborators include UTMB’s Galveston National Laboratory, Yale University, University of Maryland Human Virology Institute, HIV/AIDS Vaccine Immunology Center, National Cancer Institute, National Institutes of Health AIDS Division, Bill And the Melinda Gates Foundation, the International AIDS Vaccine Initiative, the AIDS Vaccine Trial Network and the AIDS Clinical Trial Group. Profectus is funded by Cross Atlantic Capital Partners (“XACP”) in Radnor, Pennsylvania. The main investor in XACP is the Pennsylvania Public School Employees Retirement System (“PSERS”). For more information, please visit www.profectusbiosciences.com

Medisun Regenerative Medical Center and Health Summit

Cancer Vaccine | White House Cancer Lunar Plan | Cancer Proton Beam Treatment

ShenZhen- Hong Kong-GuangZhou

The Medisun Medical Health Summit, co-sponsored by Medisun Regenerative Medical Group, New Life Group and Sunshine Medical Group, was held in Shenzhen, Hong Kong and Guangzhou from September 6 to 9, 2017. The theme of this summit is centered around the prevention and treatment of cancer. The authoritative release of cancer vaccine is the strongest focus of this summit.  

Medisun Medical Group has invited a number of authoritative scientists, medical experts, industry leaders, government agency representatives, business leaders and socialites from the United States, Europe, Japan, Hong Kong and Mainland China to collaborate on cancer prevention worldwide. Leading medical health consultations such as therapeutic technologies, industry regulatory development, and medical platform construction have been fully explored. Nearly 5,000 entrepreneur representatives, medical experts and doctors from the Chinese health industry participated in the listening and sharing.

Dozens of media interviews and reports at the summit

Madison Cancer Vaccine Launch Ceremony

Chairman Danny Wong said: “The advent of cancer vaccine is the strongest gospel of cancer prevention!”

According to the World Health Organization (WHO), approximately 14 million new cancer cases are diagnosed each year worldwide, and this number is expected to reach 21 million by 2030. As global treatment costs rise, cancer prevention measures are becoming more and more important, which has also made cancer prevention and treatment a high-profile international issue. Medisun’s comprehensive introduction of cancer vaccines is undoubtedly the strongest gospel for cancer prevention. The WT1 gene is a gene representing tumorigenesis in humans, and all human cancers are associated with this genetic mutation. The Nobel Institute of Ecological Medical Sciences has discovered a pathway to inhibit mutations in the WT1 gene, which can be vaccinated to produce memory T cells that inhibit WT1 gene mutations, which are immune to humans.

In addition, Medisun is also committed to the development and clinical use of a variety of other vaccines. Most of the vaccine technology comes from the United States, investing in rapid response to the pandemic virus and cancer control vaccine technology platform, with a market size of more than 2 billion US dollars. The vaccines invested by Medisun can be modularized in Asia and China to produce vaccines that are fully compliant with the United States. Including: Zika virus, Chikungunya fever, Zika/Chikununya heat combination, Ebola virus, human papillomavirus HPV treatment vaccine, head and neck cancer, cervical cancer, cervical lesions, simple Herpesvirus HSV, hepatitis C virus HCV, hepatitis B virus HBV,etc.

Mr. Danny Wong, Chairman of Medici Medical Group, was interviewed by the media about the release of cancer vaccine.

Chairman Danny Wong specifically said: “China’s rapid economic development over the past 20 years has been accompanied by a wave of globalization. China has integrated into the international community in various fields. At the same time, China has introduced high-standard medical technologies and services from Europe, the United States and Japan. It is our mission to make full use of Hong Kong’s advantages as a mature international metropolis and special geographical factors to provide the world’s most advanced medical care to the people of the motherland.

On-site participants actively asked questions from the cancer vaccine and new cancer treatment technologies to participate in the seminar.

Medisun participates in the White House Cancer Month Plan

Mr. Terry Lierman said: “The greatest progress and breakthrough of mankind is the birth of cancer vaccine!”

Mr. Terry Lierman, a core member of the White House Cancer Month Program, the NIH of the National Institutes of Health, and the founder of the FDA Board of Directors and director of the Meditech Group, said that cancer landing is an amazing cause. It is planned to complete the treatment of 20,000 cancer patients with 60 different technologies worldwide by 2020. This is a task that would have taken at least 10 years to achieve, and we will now achieve it in 5 years. The cancer “moon landing plan” advocated by former US President Barack Obama in 2016 is also the focus of this summit. The plan is led by former Vice President Joe Biden. The goal is to break the boundaries that hinder the cooperation of researchers and accelerate the research of cancer diagnosis and treatment in the future. 5 years to double the progress of anti-cancer research. The six major US cancer “moon landing programs” include cancer vaccines, high-sensitivity cancer early detection, immunotherapy and combination therapy, single-cell genomic analysis of cancer cells and tumor microenvironment cells, new treatments for childhood cancer, and enhanced data. shared. To this end, the United States and Canada, Hong Kong, Germany, Switzerland, Japan, South Korea and other countries, the first-class research units to establish cooperative relations, large-scale joint cancer research and treatment, toward precision Medisun. The Medisun Medical Group is a member of the Cancer Month Program and will also participate in this historic mission.

Mr. Terry Lierman talks about McGrady’s participation in the White House Cancer Month Plan

Medisun introduces Mayo proton beam therapy

Dr. Michael Haddock said: “The Mayo proton beam is a great advancement in the precise treatment of cancer!”

As the Asian Medical Service Center of the Mayo Clinic in the United States, Medisun invited Dr. Michael Haddock, Chairman of the Mayo Radiation Oncology Clinical Practice Committee and Vice Chairman of the American Society of Surgery Oncology (ACOSOG) Committee to talk about radiotherapy for cancer. Dr. Haddock talked about the current Proton Bean, the world’s leading cancer radiotherapy technology, Mayo currently has the most authoritative equipment, operations and medical team for global proton beam therapy. Mayo’s proton beam therapy program is the exclusive feature of pen beam scanning. It can accurately target tumors and prevent healthy tissues from being affected, thus achieving ideal cancer treatment, especially for treating children with cancer. For cancers with high mortality and lung cancer, proton beam therapy has obvious advantages compared with traditional radiotherapy.

At the Hong Kong Summit, Dr. Michael Haddock (left), the authoritative doctor of Mayo cancer proton beam therapy, answered questions from guests at the scene.

Dr. Michael Haddock (left) and Mr. Terry Lierman (right), the authoritative doctors of Mayo cancer proton beam therapy, at the Guangzhou Summit.

Japanese NKT immune cell therapy

Dr. Degang said: “Cancer vaccine and NKT immune cell therapy are the strongest partner in cancer prevention and treatment!”

Haruhiro Tokuoka, CEO of Riken Immunization and Reproductive Medisun, Japan, Dr. Degang Governing, talked about immunotherapy for cancer. Japan has always been a pioneer in cancer immunotherapy and has extensive clinical experience. Japan Riken and Medisun have worked closely together and established the Medisun Precision Medical Joint Venture, which applies NKT immunocytotherapy outside the traditional cancer treatment to clinical treatment of various types of cancer in the early, middle and late stages, and has clinically proven to greatly improve cancer patients. High quality of immunotherapy at the same time as quality of life with almost no side effects.

Dr. Kazuoka Kazuo of Japan at the Hong Kong Summit to explain the effectiveness of NKT immune cell therapy in clinical treatment of cancer.  

Dean He Jianxing (second from right) of Guangzhou Medical First Hospital visited the Guangzhou Summit and participated in Dr. Degang Zhiwei (third from left) on cell immunotherapy

Precision Medisun and anti-cancer cancer

Ms. Yanglan said: “As a mother, I chose to give my daughter a HPV cervical cancer vaccine; now the launch of the cancer vaccine is even more exciting!”

In today’s society, everyone is tired of work, and it is often the easiest to ignore their good habits, which leads to the emergence of various diseases . In fact, “health is the first wealth of life”, Emerson’s famous interpretation perfectly interpreted the importance of a healthy life to people. Ms. Yang Lan, a well-known Chinese media person, attended the summit as a guest and shared ideas about health and happiness with the guests. She said that the pain caused by cancer patients to the family cannot be expressed in words, and health is good for every family. Precious, we need to follow the development of science and technology to update our medical knowledge. Nowadays, precision Medisun has brought us new choices. While we are not blindly following, we should fully understand the physical condition of ourselves and our families, and choose the right medical health program for ourselves.

Ms. Yang Yu shared about cancer treatment.  

Ms. Wu Shuqing, the Honorary Director of the World Trade Center Association and the Standing Committee of the National Committee of the Chinese People’s Political Consultative Conference, was unable to visit the summit due to the temporary overseas meeting. She also sent a congratulatory message to the summit and congratulated Chairman Danny Wong of the Medisun Medical Group: “The summit has deepened Hong Kong with the Chinese mainland again, we are highly concerned about the medical and health industry. Therefore, I believe that Medisun Medical Group will continue its leading position in the field of medical and health care. Since the beginning, I have seen the entire team of Medisun under the leadership of Chairman Danny Wong. Unremitting efforts and dedication, I am convinced that today’s event is only the beginning, I hope that more results will be shared with the whole society.”

As a pioneer in the field of stem cells, cancer prevention and treatment in the world of regenerative , Medisun Medical Group has been committed to introducing the world’s leading cancer prevention and treatment technologies and providing the most advanced, professional and excellent medical and health services to the society. The release of the cancer vaccine is a revolutionary advancement in the field of cancer prevention. Ancient smallpox is terminally ill, and now a single shot of smallpox disappears; in the past, hepatitis B was terminally ill, and now a vaccine is immunized for life; yesterday, cancer is terminally ill, and today’s cancer vaccine keeps cancer away. Time is advancing and science is progressing. We must have a mentality of accepting progress. We believe that cancer prevention can provide shelter for the family and the health and well-being of  society.

Stay tuned: Hong Kong’s latest publication “CAPITAL” magazine in September, cover story “Mr. Danny Wong, Chairman of Medisun Medical Group” and cover story “New Revolution in Medical Industry”.

You can contact the Hong Kong Medisun Regenerative Medical Center to receive a magazine. Contact as below:

Phone: +(852) 2582 0188

Email: info@medisun.hk

WeChat: medisuninfo

Website: www.medisun.hk

****************************************

Medisun Medical Group

Medisun Medical Group is a professional medical investment group dedicated to the research and development and commercialization of global regenerative  products, as well as top hospitals and treatment centers. Located on the 25th floor of Ao Teng Plaza, Kowloon Bay, Hong Kong, the Medisun Reproductive Centre has a 50,000-square-foot stem cell GMP production facility, a cancer treatment centre and an anti-aging centre. It brings together European, Japanese, American and individual Chinese experts to be rigorous and professional. The development process provides immune cell therapy and a variety of stem cell health treatments. As the Asian service organization of Mayo Clinic, the center provides Mayo remote consultation and secondary treatment to enable Chinese patients to enjoy authoritative medical services without leaving the country. More than 3,000 biomedical tests provide the most predictable health protection for the health of our clients. Medisun has been fully supporting the development of the new life and health platform, and is committed to the deepening of the new products and technologies of regenerative Medisun through this platform, truly benefiting the health of the whole society.

For more details, please visit http://www.medisun.hk/

Asian’s Godfather of Cord Blood, Professor Takahashi Tsuneo Joined the “Cryolife Cord Blood Bank” and “Hong Kong Medisun”

In May 2017, CRYOLIFE Cord Blood Bank (Hong Kong Medisun Medical Group members) formally appointed the Godfather of Cord Blood in Asia, Japanese regenerative medicine expert Professor Takahashi Tsuneo as the Chief Scientist. Professor Takahashi will lead all the cord blood stem cell research projects. Professor Takahashi has eras of experience in the field of regenerative medicine. In the past few decades, Professor Takahashi has established the standards of the Cryo-Cord Blood in Asia and lead a new prospective in the application and development of the cord blood industry.

It is well believes that by the joining of Professor Takahashi will convey a new development stage in the field of cord blood stem cells in Hong Kong. It will bring new opportunities for the expansion of Medisun Medical Group and the Cryolife Cord Blood Bank.

Professor Takahashi Tsuneo is committed to the field of regenerative medicine for more than 40 years (mainly in the field of stem cells and cord blood bank). Currently he serves as Chief Executive Officer of Japan LIFEBANK and Chief Scientist of Hong Kong Cryolife Cord Blood Bank (Cryolife is a members of the Medisun Group). Prof. Takashi Tsuneo graduated from the Hokkaido University in Sapporo, Japan with a Ph.D. degree. He became the scientist in the Red Cross of Bethesda, Maryland. He later worked at the Research center for Arthritis, Diabetes and Kidney diseases of the National Institutes of Health in Bethesda, Maryland. Professor Takahashi Tsuneo returned to Japan, became the Red Cross Hokkaido Blood Center’s Research Director in Sapporo. Professor Takahashi is not only a founding member of the International Cord Blood Bank Alliance (NETCORD), but also Director of the Tokyo Cord Blood Bank Cell Treatment Center at the University of Tokyo, Japan, and Director of Cellular Research and Development for research center for cell therapy in New York. Professor Takahashi is a Visiting Professor at a number of well-known institutions, including: Department of Cellular Processing, Institute of Medical Sciences, University of Tokyo, Head of Hematology, Tokyo University Hospital, Head of Embryonic Stem Cell Research, Faculty of Forensic Medicine, Kyoto University, Kobe University Institute of Medicine and Pathology, and Department of Medicine, Peking University, China.

Application of Cord Blood

Cord blood is originated in the fetus, and collected at the umbilical cord ligation when separated from the residual placenta. Nearly a decade of research and discovered that umbilical cord blood contain the human hematopoietic and the hematopoietic stem cells of the immune system. It can be used for hematopoietic stem cell transplantation, for the treatment of more than 80 kinds of diseases. Thus, the cord blood has become an important source of hematopoietic stem cells, especially for no directly related family members. The hematopoietic stem cells is a very important human biological for treatment of diseases.

Worldwide, cord blood has been used to treat various types of Leukemia, Aplastic Anemia, Lymphoma, Multiple Myeloma, Neuroblastoma, Mucopolysaccharide disease, Thalassemia, Bone Marrow Dysplasia syndrome, Primary Immunodeficiency Disease, Chronic Granuloma and other 80 kinds of diseases.

Clinical application case

* The world’s first cord blood transplantation: In 1988, a 5-year-old French boy, suffering from Cooley’s Anemia has been treated with the cord blood transplantation and with completely recovered.
* The world’s first autologous cord blood transplantation: In 1997, a 14-month-old Brazilian girl, with autologous cord blood successfully cured Neuroblastoma.
* The world’s first double dosages of cord blood transplantation: In 2000, the Institute of Hematology of the Peking University used the world’s first double dose of cord blood transplantation for the treatment of Acute Lymphoblastic Leukemia with good result. Now, the patient weight of 95 kg, is having a healthy life.
* Asia’s first autologous cord blood transplantation: In 2009, Beijing Children’s Hospital, a pediatric patient using his own cord blood for the treatment of Neuroblastoma. This is the first case of autologous cord blood treatment for pediatric case. The baby is treated and being fine after the transplantation.
* China treated a youngest and light weight baby: In 2009, Shanghai Dao Pei Hospital has successfully treated a 2 months old baby only weight – 5 kg, by using the cord blood transplantation treatment for Primary Immunodeficiency Disease.
* In China, the first mother received the son’s cord blood transplantation as treatment: In 2009, Chongqing Xinqiao Hospital, a female patient suffering from an Acute Non-Lymphocytic Leukemia was treated by using her son’s umbilical cord blood, together with his husband’s bone marrow for transplantation. She was discharged from the Intensive Care Unit after one month from the transplantation. This is the first case of mother using her child’s cord blood for transplantation.

Treatment prospects

Cell therapy has been a biological way for the treatment of a number of diseases in the 21st century. At the end of May 2014, the worldwide of related clinical research on the cord blood cell therapy, registered with the United States National Institutes of Health (NIH) reached a total of 928.

CRYOLIFE Cord Blood Bank – Hong Kong’s first private cord blood bank

CRYOLIFE Cord Blood Bank is the only one in Hong Kong with the most international professional certification, and is highly recommended by gynecologist, physicians and parents. CRYOLIFE was established in 1996 to create the first private cord blood storage program in Asia. Prior to the establishment of the cord blood bank in Japan, Singapore, mainland China, Taiwan and Malaysia. Cryolife upgrades the standards in the development and research in the laboratory equipment. It is the leader in Hong Kong and Asian in the cord blood industry. CRYOLIFE has been recognized by the American Association of Blood Banks (AABB) since 2007 as one of the world’s first recognized AABB-approved cord blood banks, and range the first 50 in the Cord Blood Bank’s list. Continuous assessment were done in 2009, 2011, 2013 and 2015 and has successfully passed the review, and gain the AABB certification until the end of 2017. The company is the only one in Hong Kong which has obtained a 10 consecutive years’ certification in the private cord blood bank. (In February 2017) Hong Kong Medisun Medical Group acquired 51% stake in CRYOLIFE Cord Blood Bank as its controlling shareholder.)

MEDISUN MEDICAL GROUP

Headquartered in Hong Kong, Headquartered in Hong Kong, the company is committed to investing in R & D and commercialization of global regenerative medicine products, as well as professional medical investment groups in top hospitals and treatment centers.

Medisun invests extensively in regenerative medicine and stem cell patented technology, including stem cell therapy for heart failure, stem cell therapy for liver disease, kidney disease, neurological diseases, cancer, AIDS, and immune cell therapy for a variety of cancers. Medisun Medical and the US Mayo Clinic, Harvard University Stem Cell Research Institute, Johns Hopkins School of Life Science Center launched a long-term cooperation program, co-investment in regenerative medicine and stem cell therapy technology. Medisun collaborates with them as the business owned holdings and holds global intellectual property rights.

The Medisun Regenerative Medical Center is located in Kowloon, Hong Kong , with 50,000 square feet of stem cell GMP production base, cancer treatment center and anti-aging center, bringing together European, Japanese, American and individual Chinese experts for rigorous professional development process by providing immune cell therapy and a variety of stem cell treatments. Medisun is also the Asian Center, a representative of the Mayo Clinic Asia service agencies. It provides Mayo remote consultation, the second diagnosis and treatment, so that Chinese patients can not enjoy the authority of the medical services. Mayo Clinic provides more than three thousand biomedical tests for the most predictable health protection for our customers’ health.

Medisun Regenerative Medicine Center (Mayo Asia Medical Service Center | Cancer Treatment Center | Anti-Aging Center)

Medisun Medical Laboratory (Hong Kong)

Source : http://www.medisun.hk/

The famous American virologist – HIV virus discoverer Robert Gallo joined Medisun Medical Groupedisun

Bringing the best cancer and AIDS treatment technologies to China

Robert Gallo, a famous American virologist, joined Medisun Medical Groupedisun

In February 2017, Medisun Medical Group officially announced the appointment of Robert Charles Gallo, a famous American virologist, as a member of the board of directors of the group.

 

Dr. Robert Charles Gallo

Dr. Gallo is a famous American virologist whose best-known contribution is the discovery of the first human retrovirus (HTLV1, and HTLV2). In 1983, HTLV3 was discovered, which was later called the HIV, a virus that causes AIDS. He also studied the cytokine leukocyte 2, and in 1986 studied the pathogen human rash type 6 virus in children with acute rash. In 1982 and 1984, he received the Lasker Basic Medical Research Award (known as the “Nobel Prize in the United States”), the Charles Mott Award (Tumor Prevention Contribution Award) in 1984, and the Dickson International Award in 1985, 1988. Received the National Science and Technology Outstanding Contribution Award from Japan. Dr. Gallo is currently the Director of the Institute of Human Virology (IHV) at the University of Maryland and the founder and chief scientist of the Global Virus Network (GVN). He has served in the National Cancer of the United States. The National Cancer Institute has served as the director of the Laboratory of Cancer Cell Biology for 30 years. Dr. Gallo proposed the theory that the tumor system is caused by viruses and gradually improved its academic structure and clinical research.

Mr. Terry L. Lierman, founder of the US FDA, joined Medisun

At the same time , Mr.Terry L. Lierman entered the board of Medisun. Mr. Lierman is the founder of Summit Global Ventures and the CEO of Health Ventures LLC.Mr. Lierman has served on the US Senate Appropriations Committee and served as Director of the Sub-Committee on Labor Health and Human Services (HHS) Grants. Mr. Lierman is also the founder of Research America and NIH (National Institutes of Health) / FDA (US Food and Drug Administration) Board of Directors, and serves as the majority leader and member of the House of Representatives. He began his career in the health field of the NIH (National Institutes of Health) in 1971, where he assisted with budget and policy development, grants and contracts. For the past four decades, he has combined entrepreneurs and political talent in a variety of businesses.From leadership positions in the US Senate Appropriations Committee, founding companies and non-profit organizations, to promote health care advocacy, to lead and serve as chairman of the Maryland Democratic Party.

Mr.Terry L.Lierman

Chairman Medisun Wang Xiaofeng joined the Board of Directors of the Institute of Human Virology and the International Virus Alliance

At the same time that two world-class companies joined Medisun, Mr. Wang Xiaofeng, Chairman of Medisun Medical Group, was also invited to the Institute of Human Virology (IHV) and the Global Virus Network (GVN) at the University of Maryland as a member of the board of directors. Mr. Wang is the founder and chairman of the Board of Directors of Medisun Medical Group living in Canada and the United States for ten years. He moved to Hong Kong in 1996. Mr. Wang has more than 20 years of experience in the global capital market and medical industry, including industries including Medisunne, internet, education and media. Mr. Wang is currently Chairman of Hong Kong-listed National Investment Fund (01227.HK) and Chairman of Beijing Financial Group.

Mr. Danny Wong

Headquartered in Hong Kong, Medisun Medical Group is a professional medical investment group dedicated to the research and development and commercialization of global regenerative Medisunne products, as well as top hospitals and treatment centers.

Medisun invests extensively in the fields of regenerative Medisunne and stem cell patent technology, including stem cell therapy for heart failure, stem cell therapy for liver disease, kidney disease, nervous system disease, cancer, AIDS, and immune cell therapy for a variety of cancers. Medisun Medical has a long-term cooperation plan with the US-Australia Clinic, the Harvard University Stem Cell Institute, and the Johns Hopkins Medical School Life Science Center to jointly invest in regenerative Medisunne and stem cell therapy technology, with Medisun as a co-operative business. The Medisun holding entity and holds global intellectual property rights.

The Medisun Reproductive Medisunne Centre is located at the Proud Square in Kowloon Bay, Hong Kong. It has a 50,000 square foot stem cell GMP production base, a cancer treatment centre and an anti-aging centre. It brings together European, Japanese, American and individual Chinese experts to develop a rigorous and professional R&D process. Provides immune cell therapy and a variety of stem cell health treatments. As the Asian service organization of Mayo Clinic, the center provides Mayo remote consultation and secondary treatment to enable Chinese patients to enjoy authoritative medical services without leaving the country. 3,300 biomedical tests provide the most predictable health protection for customers’ health, adding more than 300 new testing items each year.

MEDISUN REGENERATIVE MEDICAL CENTER | CANCER TREATMENT CENTER | ANTI-AGING CENTER

Medisun Medical Laboratory (Hong Kong)

Medisun Medical Laboratory (Hong Kong)

Medisun announced that he will join the Biden Cancer Lunar Plan

At the end of 2016, Medisun announced that he would join the “Cancer Moon Plan” initiated by former US Vice President Biden. The “Cancer Moon Plan” was proposed by former US President Obama in early 2016 and was initiated by former Vice President Biden. The goal is to shorten the work schedule for cancer-related prevention, diagnosis, treatment and care that was expected to be completed in 5 years. Aiming to achieve 20,000 cancer treatments worldwide by 60 programs by 2020.
Dr. Gallo and Mr. Lierman will lead Medisun’s clinical research implementation, medical technology and project selection, medical resource introduction, etc., and bring the best technology in the world to China, highlighting the inevitable trend of China’s participation in the world’s most advanced technology research and development. . At the same time, Medisun’s clinical research bases in Hong Kong, Beijing, Shanghai, Guangzhou and Tokyo will participate in the world’s most advanced clinical research.
Dr. Gallo and Mr. Lierman joined Medisun and Chairman Wang Xiaofeng to enter the IHV and GVN Board of Directors, indicating that Medisun will work with IHV and GVN to make valuable preparations for the cancer landing program and to fully participate in the global research and development of cancer treatment.

The Human Virology Institute (IHV) is the world’s first research center that combines basic science, epidemiology and clinical research disciplines to accelerate the diagnosis and treatment of chronic viruses and immune diseases (mostly HIV, AIDS the reason). IHV’s laboratory is a US key laboratory that receives more than $200 million in annual US research funding.
Founded in 1996 as a partner of the University of Maryland, IHV is a research institute at the University of Maryland School of Medisun, bringing together a globally recognized and world-renowned expert in human virology. The IHV was co-founded by Robert Gallo (Director of IHV) and William Blattner.MD. The IHV also includes the Animal Model Department, the Basic Science Department and the Vaccine Research Department.
The institute has a variety of laboratory and patient care facilities located in Baltimore, Maryland. IHV has created an environment of close collaboration between multidisciplinary research, education and clinical research and development, accelerating scientific understanding of the incidence of HIV/AIDS, and developing interventions to curing cancers of HIV and viruses possible.
IHV’s research focuses on how to use the body’s natural chemistry to its own therapeutic potential, and to discover biotherapeutics that are less toxic to the body and more economical for the public. IHV is also committed to developing effective therapeutic and preventive vaccines that are dedicated to ending the AIDS epidemic.
IHV has more than 300 employees, including 70 professors, whose research focuses on chronic human viral infections and diseases. Currently, more than 75% of the Institute’s clinical and research work addresses HIV infection, but also includes hepatitis C virus, human T-cell leukemia virus 1 and 2, human papillomavirus, herpes virus and cancer research. The patient base of IHV has grown from just 200 patients to about 6,000 in Baltimore, and nearly 1 million in 6 African and 1 Caribbean countries.

The Global Network of Viruses (GVN) is a global organization for the research of viral diseases. It is a consortium of authoritative virologists from more than 20 countries around the world. It is dedicated to the research, development of drugs and vaccines to prevent diseases and death. GVN is the only single organization in the world that has special research in all areas of the virus. GVN brings together the world’s best medical virology experts to focus on difficult scientific issues around the world. The strength of GVN lies in its global reach, the depth of science, and its vision to address the viral challenges facing humanity.

GVN achieves its goals through three strategic action platforms:

Support research

Public education

Advocate a statement supporting the global virus network

Established in Washington, DC, the organization supports the goals and ideals of a global virus network, actively trains younger generations of medical virologists, and provides advice to governments or NGOs on viral diseases to fill the current international health development important needs.

Source: http://www.medisun.hk/

Hong Kong National Investment and Harvard University Stem Cell Institute have a strong cooperation.

Mr. Brock Reeve, CEO of Harvard Stem Cell Research Institute, is the Chief Investment Officer of Stem Cell and Regenerative Medisun at National Investment and Medici Medical Group.

2015-05-11 China Securities Journal

On May 8, 2015, Hong Kong Medisun Regerative Medical Center and National Investment (01227.HK) announced the appointment of Mr. Brock Reeve as the chief stem cell and regenerative medicine investment officer of the two companies.

Mr. Brock Reeve is currently the Executive Director of the Harvard University Stem Cell Institute and has graduated from Yale University and Harvard Business School. Mr. Reeve is solely responsible for the strategy and operations of the Harvard Stem Cell Institute, whose overall goal is to use stem cell biology as a tool and treatment to study and treat major degenerative diseases.

As the Chief Investor of Stem Cell and Regenerative Medicine of Medisun Medical Center, Mr. Brock Reeve will organize and lead a professional investment team to actively select the latest regenerative medicine technologies in overseas markets such as Europe, the United States, and Japan and evaluate their investment value. They will also focus on and invest in the world’s leading stem cell regenerative medicine technology, and actively participate in clinical trials and product commercialization of stem cell technology invested by Medisun Medical Center in Asia.

Medisun Medical Center is the world’s most authoritative investment organization in stem cell and regenerative medicine

As the world’s most authoritative investment organization for stem cells and regenerative medicine, Medisun Medical Center has invested in stem cell treatment technologies including heart, tumor, liver, kidney, AIDS and other diseases, fully demonstrating its investment vision and courage. After working with the Mayo Medical Group in the United States, the Medisun once again joined forces with the Harvard University Stem Cell Institute.

Mr. Danny Wong is both the Chairman of the Medisun Medical Group and National Investment (01227.HK). He has devoted himself to research and investment in the field of stem cells for the past five years. The Medisun currently has more than 300 scientists , medical consultants and investment experts from all over the world. The technologies invested by the group are distributed in Europe, the United States, Japan, Hong Kong and other places, and clinical trials are carried out simultaneously.

China’s first participation in international multi-center global synchronized clinical trials

Medisun Medical Group is committed to bringing the world’s leading stem cell and regenerative medicine technologies to China. The investment in the C-cure stem cell therapy for ischemic heart failure technology, which was invented by Mayo Medical Group, has been clinically tested in Europe and the United States. It will carry out clinical trials in China’s well-known cardiovascular hospitals such as Beijing Anzhen Hospital, Fuwai Cardiovascular Hospital and Shanghai Oriental Hospital with the support of international multi-center policy, giving Chinese hospitals the opportunity to participate in the world’s most advanced stem cell technology clinic. The Medisun also actively promote the commercialization of technology worldwide in the future. Before C-Cure’s great technology and revolutionary products for heart disease were officially launched, Medisun has launched a series of cell regeneration factor products to treat a number of diseases, and the product has entered the market.

Liang Zhen ying visits Harvard University Stem Cell Research Institute and Mr. Brock Reeve to discuss the promotion of stem cell and the development of regenerative medicine industry

Under the general environment of Hong Kong’s adjustment of the whole industry, one of the important measures is to develop the stem cell and regenerative medicine industries. Looking at the huge investment in the stem cell and regeneration field of the Medisun Medical Group, it is revealed that it will inevitably set off a disruptive business model in the market.

The Hong Kong government attaches great importance to the development of stem cells. Following the cooperation with the Caroline Medical School in Sweden, Liang Zhen ying visited the Harvard University Stem Cell Research Institute on May 5 and exchanged views with its Executive Director Brock Reeve to promote the development of the stem cell industry in Hong Kong. This will undoubtedly inject a strong shot into the cooperation between Harvard University and Hong Kong in the field of regenerative medicine. It will promote the promotion of Harvard stem cells in regenerative medicine research and technology in Hong Kong and Asia.

It can be seen that Medisun Medical Group has appointed Mr. Brock Reeve take the helm of the stem cell and regenerative medicine to investment. National Investment (01227.HK), which holds a 30% stake in Medisun Medical Group, is investing in regenerative medicine and the field of stem cells. Mr. Brock Reeve will lead the Medisun Medical Group to become a professional stem cell investment team with global leadership.

The value of the stem cell and regenerative medicine industry under the capital market in China and Hong Kong is immeasurable.

With the upcoming clinical management of stem cells, the development of China’s stem cell and regenerative medicine industry will be unstoppable. Shanghai-Hong Kong Stock Connect and the upcoming Shenzhen-Hong Kong Stock Connect have apparently injected huge sums of money into Hong Kong stocks. The stocks of companies related to the stem cell industry have risen very well, but they are far from satisfactory and far from the technology held by Medisun Medical Center. National Investment (01227.HK), as a shareholder of Medisun Medical Group, is full of confidence in the development of the Group.

Medisun Investment Holdings’ Cardio Biotech plans to enter the US capital market.

Medisun Investment Holdings’ C-cure Stem Cell Therapy for Ischemic Heart Failure has exceeded the number of patients enrolled by the European Food and Drug Administration (EMA) in the Phase III clinical trial in Europe and has been approved by the US Food and Drug Administration (FDA). Enter the third phase of clinical. Cardio, the investment holding company of Medisun, also successfully obtained a new round of financing of 32 million euros in February this year. Its financing quota was oversubscribed and snapped up by European and American institutional investors. Cardio is planning to be listed on the NASDAQ in the United States from the end of May to the beginning of June this year (listed in Belgium and France in 2013), and the large-scale financing plan of Cardio further indicates that the spring of stem cells has really come.

After many years of favor and investment in the field of stem cells and regenerative medicine, and the huge capital investment plan, the Medisun’ next step will be the focus of the market. The capital market’s confidence in its shareholder, National Investment (01227.HK), is already evident in the expectation of its future development.According to analysts, Medisun has planned to launch an overall listing financing plan in Hong Kong in the near future. We believe that Medisun, as a recognized leader in the global stem cell and regenerative medicine field, will surely launch an incredible wave of development in this field.

The News Picture:

P1:

Mr. Brock Reeve is both the chairman of Medisun medical group and National Investment (01227.HK) and a close friend of Mr. Danny Wong during his stay in the United States.They share the same confidence and enthusiasm for stem cell and regenerative medicine.

P2:

Hong Kong Chief Executive Liang Zhen ying visited the Harvard University Stem Cell Institute and exchanged views with the Executive Director, Mr. Brock Reeve, on the development of the stem cell and regenerative medicine industries.

Source: http://www.medisun.hk/

Brock Reeve is the younger brother of the famous American actor Christopher Reeve. Christopher Reeve (September 25, 1952 – October 10, 2004), a New Yorker, famous movie actor, film director, writer, was play in Superman (Kal-El/Clark Kent). He graduated from Cornell University in 1974 with a Bachelor of Arts degree and then entered the Juilliard School in New York. He is also a good friend with another famous actor Robin Williams. In 1978, he starred in the sci-fi film “Superman” for the first time and became a hit. In 1995, an accident occurred during an equestrian competition. The spine was seriously injured and his body was paralyzed. Since then, he has devoted himself to social welfare undertakings and to promote stem cell research. He often holds tour lectures. On October 9, 2004, he died for the myocardial infarction at the age of 52.

Medisun Medical Group 2015-01-26,

Taking the first year of China’s medical reform in 2015 as an opportunity, Mayo and Medisun have joined forces to enter the Chinese medical market in large numbers. It can be said that it is at the right time. Dr. Cao Shengyu, President of Medici Medical Group, former General Manager of Hong Kong Queen Elizabeth Hospital and General Manager of Kowloon China Network and managing the five public hospitals, said: “Based on our experience in investing in hospitals in Hong Kong and China over the past 20 years, and in the new environment of China’s medical system reform, Medisun is confident to introduce Mayo’s advanced medical service system to China and benefit patients. According to the GATT and the planning process of a number of specific work agreements, we will gradually provide Mayo’s medical services from Hong Kong to Beijing and Shanghai.

The establishment of the Mayo affiliated hospital system have truly brought Mayo’s world-class medical care to Chinese patients. Dr. Cao was the President of the China Hospital Society HCA (Hospital Corporation of America), responsible for establishing sino-American joint venture hospital in China.

On January 22, 2015, at the strategic cooperation ceremony between Mayo and Medisun, Mayo President Jeffrey Burton led the Mayo executives to accept the Chinese Song Dynasty Tiansheng Acupuncture Copper Man presented by Chairman Madison

Dr. Zhang Yuanxin, senior vice president of Medisun Medical Group and senior bio-industry analyst on Wall Street in the United States, joined Medisun in recognition of Medisun’s expectations for regenerative medicine and China’s healthcare reform. He said, “The cooperation between Mayo and Medisun began with Medisun’s investment in cutting-edge technologies in regenerative medicine.

The two sides have reached a high consensus on the concept of developing medical services in China. Mayo values Medisun’s strategic position in connecting Hong Kong and connecting things. And Medisun’s existing advanced medical facilities and experienced management team, and reached a long-term cooperation agreement with Medisun. This understanding and understanding laid a solid foundation for the cooperation between the two, and the real benefit is the Chinese patients.

Source: http://www.medisun.hk/